{"success":true,"data":{"pressRelease":{"id":"170351","rtpr_id":"nPn57mqf1a-20261015","ticker":"ATNM","exchange":"NYSE American","all_tickers":["ATNM"],"title":"Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer","author":"PR Newswire","published_at":"2026-10-15T12:30:02.309Z","article_body":"Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer\nPR Newswire\n\nNEW YORK, Oct. 15, 2026\n\n * Early clinical data from the Phase 1 theranostic trial support the advancement\nof ATNM-400 as a non-PSMA targeted alpha therapy for metastatic\ncastration-resistant prostate cancer (mCRPC)\n * Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution,\nand dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a\ntargeted radiotherapy\n * ATNM-400 is a first-in-class, non-PSMA targeted radiotherapy being developed\nto address a broad mCRPC patient population, including PSMA-low and\nPSMA-negative disease and patients who do not respond to or progress following\nPSMA-directed therapies\nNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE\nAmerican: ATNM) (Actinium or the Company), a pioneer in differentiated\ntargeted radiotherapies with the potential to transform cancer treatment,\ntoday announced that an oral presentation with early results from the\nfirst-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant\nprostate cancer (mCRPC) will be presented at the 39th Annual Congress of the\nEuropean Association of Nuclear Medicine (EANM), October 17–21, 2026, in\nVienna, Austria.\n\nThe oral presentation will highlight the ongoing first-in-human Phase 1\ndose-escalation study of ATNM-400 in mCRPC. ATNM-400 is a first-in-class\nActinium-225 (²²⁵Ac) antibody radioconjugate targeting a non-PSMA antigen\nimplicated in tumor survival and treatment resistance. The study will\ncharacterize the safety, biodistribution, and dosimetry of\nZirconium-89-labeled ATNM-400. Serial PET imaging will assess its tumor\nuptake, distribution, and clearance, with dosimetry estimates informing\ntherapeutic ²²⁵Ac-ATNM-400 dosing.\n\n\"These first clinical data from ATNM-400 mark an important milestone for\nActinium and for prostate cancer treatment beyond PSMA,\" said Sandesh Seth,\nActinium's Chairman and CEO. \"As a first-in-class radiotherapeutic targeting\nan antigen implicated in tumor survival and treatment resistance, ATNM-400 has\nthe potential to serve the broad mCRPC population, including patients with\nPSMA-low or PSMA-negative disease and those who do not respond to or progress\nafter PSMA-directed therapies. These initial findings mark an important\nmilestone for ATNM-400 and our Actinium-225 development program.\"\n\nATNM-400 EANM 2026 Presentation Details\n\nAbstract Title: First-In-Human Phase 1 Study of ATNM-400, Actinium-225\nAntibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer\n(mCRPC)\nAbstract Number: OP-525\nPresentation Type: Oral presentation\nSession: 1111 — Theranostics Track: Prostate Cancer Therapy II\nSession Date & Time: Monday, October 19, 2026, 4:45–6:15 p.m. CEST |\nVienna, Austria\nLocation: Hall G1\n\nAbout Actinium Pharmaceuticals, Inc.\n\nActinium is a pioneer in targeted radiotherapies designed to improve outcomes\nfor patients with cancer. The company employs a biology-driven approach to\ndevelop differentiated radiopharmaceuticals for solid tumors and hematologic\nmalignancies. Its mission is to transform cancer treatment through innovative\nradioconjugates that maximize therapeutic efficacy while minimizing toxicity\nto healthy tissue by combining expertise in tumor biology, translational\nmedicine, and radiochemistry. Since inception, Actinium has focused on\ndeveloping innovative radiotherapies. Its pipeline reflects this strategy\nacross three areas: (1) solid tumor therapeutics including ATNM-400 and\nActimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone\nfor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in\ncollaboration with the National Cancer Institute (NCI); and (3) targeted\nconditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT\nfor cell and gene therapy conditioning. ATNM-400 targets a novel antigen\ndistinct from PSMA and has demonstrated preclinical activity across metastatic\ncastration-resistant prostate cancer (mCRPC), non-small cell lung cancer\n(NSCLC), and breast cancer. Actimab-A has shown improved survival in\nrelapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial,\nwith additional development ongoing through a CRADA with the NCI. Actinium is\nalso advancing preclinical solid tumor programs and holds ~250 patents and\npatent applications, including intellectual property related to\ncyclotron-based production of Ac-225. For more information, please visit\nwww.actiniumpharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798452-1&h=824938262&u=https%3A%2F%2Fwww.actiniumpharma.com%2F&a=www.actiniumpharma.com)\n.\n\nForward-Looking Statements\n\nThis press release may contain projections or other \"forward-looking\nstatements\" within the meaning of the \"safe-harbor\" provisions of the private\nsecurities litigation reform act of 1995 regarding future events or the future\nfinancial performance of the Company which the Company undertakes no\nobligation to update. These statements are based on management's current\nexpectations and are subject to risks and uncertainties that may cause actual\nresults to differ materially from the anticipated or estimated future results,\nincluding the risks and uncertainties associated with preliminary study\nresults varying from final results, estimates of potential markets for drugs\nunder development, clinical trials, actions by the FDA and other governmental\nagencies, regulatory clearances, responses to regulatory matters, the market\ndemand for and acceptance of Actinium's products and services, performance of\nclinical research organizations and other risks detailed from time to time in\nActinium's filings with the Securities and Exchange Commission (the \"SEC\"),\nincluding without limitation its most recent annual report on form 10-K,\nsubsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and\nsupplemented from time to time.\n\nInvestors: investorrelations@actiniumpharma.com\n(mailto:investorrelations@actiniumpharma.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html\n(https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html)\n\nSOURCE Actinium Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1855363/FINAL-LOGO-ACTINIUM-PHARMA-Logo.jpg?id=OA3020209\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn57mqf1a-20261015","title":"Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer","author":"PR Newswire","ticker":"ATNM","created":"2026-10-15T12:30:02.309Z","tickers":["ATNM"],"exchange":"NYSE American","article_body":"Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer\nPR Newswire\n\nNEW YORK, Oct. 15, 2026\n\n * Early clinical data from the Phase 1 theranostic trial support the advancement\nof ATNM-400 as a non-PSMA targeted alpha therapy for metastatic\ncastration-resistant prostate cancer (mCRPC)\n * Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution,\nand dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a\ntargeted radiotherapy\n * ATNM-400 is a first-in-class, non-PSMA targeted radiotherapy being developed\nto address a broad mCRPC patient population, including PSMA-low and\nPSMA-negative disease and patients who do not respond to or progress following\nPSMA-directed therapies\nNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE\nAmerican: ATNM) (Actinium or the Company), a pioneer in differentiated\ntargeted radiotherapies with the potential to transform cancer treatment,\ntoday announced that an oral presentation with early results from the\nfirst-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant\nprostate cancer (mCRPC) will be presented at the 39th Annual Congress of the\nEuropean Association of Nuclear Medicine (EANM), October 17–21, 2026, in\nVienna, Austria.\n\nThe oral presentation will highlight the ongoing first-in-human Phase 1\ndose-escalation study of ATNM-400 in mCRPC. ATNM-400 is a first-in-class\nActinium-225 (²²⁵Ac) antibody radioconjugate targeting a non-PSMA antigen\nimplicated in tumor survival and treatment resistance. The study will\ncharacterize the safety, biodistribution, and dosimetry of\nZirconium-89-labeled ATNM-400. Serial PET imaging will assess its tumor\nuptake, distribution, and clearance, with dosimetry estimates informing\ntherapeutic ²²⁵Ac-ATNM-400 dosing.\n\n\"These first clinical data from ATNM-400 mark an important milestone for\nActinium and for prostate cancer treatment beyond PSMA,\" said Sandesh Seth,\nActinium's Chairman and CEO. \"As a first-in-class radiotherapeutic targeting\nan antigen implicated in tumor survival and treatment resistance, ATNM-400 has\nthe potential to serve the broad mCRPC population, including patients with\nPSMA-low or PSMA-negative disease and those who do not respond to or progress\nafter PSMA-directed therapies. These initial findings mark an important\nmilestone for ATNM-400 and our Actinium-225 development program.\"\n\nATNM-400 EANM 2026 Presentation Details\n\nAbstract Title: First-In-Human Phase 1 Study of ATNM-400, Actinium-225\nAntibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer\n(mCRPC)\nAbstract Number: OP-525\nPresentation Type: Oral presentation\nSession: 1111 — Theranostics Track: Prostate Cancer Therapy II\nSession Date & Time: Monday, October 19, 2026, 4:45–6:15 p.m. CEST |\nVienna, Austria\nLocation: Hall G1\n\nAbout Actinium Pharmaceuticals, Inc.\n\nActinium is a pioneer in targeted radiotherapies designed to improve outcomes\nfor patients with cancer. The company employs a biology-driven approach to\ndevelop differentiated radiopharmaceuticals for solid tumors and hematologic\nmalignancies. Its mission is to transform cancer treatment through innovative\nradioconjugates that maximize therapeutic efficacy while minimizing toxicity\nto healthy tissue by combining expertise in tumor biology, translational\nmedicine, and radiochemistry. Since inception, Actinium has focused on\ndeveloping innovative radiotherapies. Its pipeline reflects this strategy\nacross three areas: (1) solid tumor therapeutics including ATNM-400 and\nActimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone\nfor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in\ncollaboration with the National Cancer Institute (NCI); and (3) targeted\nconditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT\nfor cell and gene therapy conditioning. ATNM-400 targets a novel antigen\ndistinct from PSMA and has demonstrated preclinical activity across metastatic\ncastration-resistant prostate cancer (mCRPC), non-small cell lung cancer\n(NSCLC), and breast cancer. Actimab-A has shown improved survival in\nrelapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial,\nwith additional development ongoing through a CRADA with the NCI. Actinium is\nalso advancing preclinical solid tumor programs and holds ~250 patents and\npatent applications, including intellectual property related to\ncyclotron-based production of Ac-225. For more information, please visit\nwww.actiniumpharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798452-1&h=824938262&u=https%3A%2F%2Fwww.actiniumpharma.com%2F&a=www.actiniumpharma.com)\n.\n\nForward-Looking Statements\n\nThis press release may contain projections or other \"forward-looking\nstatements\" within the meaning of the \"safe-harbor\" provisions of the private\nsecurities litigation reform act of 1995 regarding future events or the future\nfinancial performance of the Company which the Company undertakes no\nobligation to update. These statements are based on management's current\nexpectations and are subject to risks and uncertainties that may cause actual\nresults to differ materially from the anticipated or estimated future results,\nincluding the risks and uncertainties associated with preliminary study\nresults varying from final results, estimates of potential markets for drugs\nunder development, clinical trials, actions by the FDA and other governmental\nagencies, regulatory clearances, responses to regulatory matters, the market\ndemand for and acceptance of Actinium's products and services, performance of\nclinical research organizations and other risks detailed from time to time in\nActinium's filings with the Securities and Exchange Commission (the \"SEC\"),\nincluding without limitation its most recent annual report on form 10-K,\nsubsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and\nsupplemented from time to time.\n\nInvestors: investorrelations@actiniumpharma.com\n(mailto:investorrelations@actiniumpharma.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html\n(https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html)\n\nSOURCE Actinium Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1855363/FINAL-LOGO-ACTINIUM-PHARMA-Logo.jpg?id=OA3020209\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T12:30:02.436848911Z","server_sent_at_ms":1792067402436},"received_at":"2026-10-15T12:30:02.487Z","source_url":"https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-oral-presentation-at-eanm-2026-highlighting-first-in-human-phase-1-study-of-atnm-400-a-non-psma-targeting-radiotherapy-in-prostate-cancer-302909267.html"},"analysis":{"id":"158540","press_release_id":"170351","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["data are early-stage Phase 1 safety/dosimetry results; preliminary results may vary from final results"],"eventType":"clinical_trial","narrative":"Actinium Pharmaceuticals will present early first-in-human Phase 1 data for ATNM-400, its non-PSMA Actinium-225 radioconjugate, in an oral presentation at the EANM annual congress in Vienna, October 17-21, 2026.\n\nThe Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer uses Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry, informing therapeutic Actinium-225 dosing.\n\nATNM-400 is a first-in-class therapy aimed at the broad mCRPC population, including PSMA-low and PSMA-negative patients who progress after PSMA-directed therapies.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"EANM oral presentation validates ATNM-400's first-in-class non-PSMA approach, but early Phase 1 data are a modest catalyst."},"keyFigures":{"drugName":"ATNM-400","phaseOfTrial":"Phase 1"},"quotedText":"These first clinical data from ATNM-400 mark an important milestone for Actinium and for prostate cancer treatment beyond PSMA","namedEntities":{"people":[{"name":"Sandesh Seth","role":"Chairman and CEO"}],"products":["ATNM-400","Actimab-A","Iomab-B","Iomab-ACT"],"companies":[{"name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM"},{"name":"National Cancer Institute (NCI)","relationship":"collaborator"},{"name":"European Association of Nuclear Medicine (EANM)","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Early Phase 1 data for ATNM-400 selected for an oral presentation at EANM 2026 — a positive visibility milestone for a first-in-class non-PSMA radiotherapy, but data are preliminary dose-escalation/safety results with no efficacy or regulatory catalyst."},"tickerRelevance":{"others":[],"primary":"ATNM"},"globalImportance":22,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"early-phase-clinical-data-presentation","noveltyBoost":"first-in-class mechanism with oral presentation selection","householdBrandBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Actinium Pharmaceuticals will present early first-in-human Phase 1 data for ATNM-400, its non-PSMA Actinium-225 radioconjugate, in an oral presentation at the EANM annual congress in Vienna, October 17-21, 2026.\n\nThe Phase 1 dose-escalation study in metastatic castration-resistant prostate cancer uses Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry, informing therapeutic Actinium-225 dosing.\n\nATNM-400 is a first-in-class therapy aimed at the broad mCRPC population, including PSMA-low and PSMA-negative patients who progress after PSMA-directed therapies.","key_figures":{"drugName":"ATNM-400","phaseOfTrial":"Phase 1"},"named_entities":{"people":[{"name":"Sandesh Seth","role":"Chairman and CEO"}],"products":["ATNM-400","Actimab-A","Iomab-B","Iomab-ACT"],"companies":[{"name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM"},{"name":"National Cancer Institute (NCI)","relationship":"collaborator"},{"name":"European Association of Nuclear Medicine (EANM)","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T12:30:22.044Z","global_importance":22,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"early-phase-clinical-data-presentation","noveltyBoost":"first-in-class mechanism with oral presentation selection","householdBrandBoost":0}},"durationMs":4888,"modelName":"glm-5.3-flashx"}}